SLAM/SLAM interactions inhibit CD40-induced production of inflammatory cytokines in monocyte derived dendritic cells

Rethi B, Gogolak P, Szatmari I, Veres A, Erdos E, Nagy L, Rajnavolgyi E, Terhorst C, Lanyi A
Source: Blood
Publication Date: (2006)
Issue: 107(7): 2821-9
Research Area:
Immunotherapy / Hematology
Cells used in publication:
Dendritic cell (NHDC), human
Species: human
Tissue Origin: blood
SLAM (Signaling Lymphocyte Activation Molecule, CD150 or SLAMF1) is a self-ligand receptor on the surface of activated T- and B-lymphocytes, macrophages and dendritic cells (DCs). Here we examine the effect of SLAM/SLAM interactions on CD40L-induced CD40 signaling pathways in human DCs. CD40L-expressing L929 cells induced DCs to produce IL-6, TNF-alpha and IL-12, which was strongly inhibited by co-expression of SLAM on the surface of the L929 cells. Similarly, transfection of DCs with SLAM strongly reduced CD40L-induced IL-12 production. Furthermore, the negative effect of SLAM/SLAM interactions on CD40L-induced DC activation was also detected in the presence of LPS. LPS-induced IL-12 secretion, however, was not inhibited by SLAM-engagement. CD40L-activated DCs affected by exposure to SLAM/SLAM engagement were impaired in their ability to induce differentiation of naive T lymphocytes into IFN-gamma producing Th1 effector cells. These inhibitory effects were not the result of a general unresponsiveness of DCs to CD40L, as SLAM/SLAM interactions did not prevent CD40L-induced up-regulation of CD83, CD86 or HLA-DQ on the surface of DCs. Taken together, the results indicate that SLAM/SLAM interactions inhibit CD40-induced signal transduction in monocyte derived dendritic cells, an effect that was not detectable in earlier studies using anti-SLAM monoclonal antibodies.